Menu Search
Equities

TG Therapeutics Inc

NKB2:BRN

TG Therapeutics Inc

Actions
  • Price (CHF)15.64
  • Today's Change0.00 / 0.00%
  • Shares traded40.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Dec 15 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year TG Therapeutics Inc grew revenues 8,290.02% from 2.79m to 233.66m while net income improved from a loss of 198.34m to a gain of 12.67m.
Gross margin92.76%
Net profit margin27.60%
Operating margin29.37%
Return on assets30.76%
Return on equity87.78%
Return on investment43.42%
More ▼

Cash flow in USDView more

In 2023, cash reserves at TG Therapeutics Inc fell by 9.36m. Cash Flow from Financing totalled 72.71m or 31.12% of revenues. In addition the company used 31.41m for operations while cash used for investing totalled 50.65m.
Cash flow per share0.6341
Price/Cash flow per share40.79
Book value per share1.15
Tangible book value per share1.15
More ▼

Balance sheet in USDView more

TG Therapeutics Inc has a Debt to Total Capital ratio of 36.61%, a lower figure than the previous year's 241.51%.
Current ratio3.58
Quick ratio2.83
Total debt/total equity0.5775
Total debt/total capital0.3661
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.